India's Dr Reddy's misses Q2 profit view on weak pricing in North America
Adds details from paragraph 3 onwards
Nov 5 (Reuters) -Indian generic drugmaker Dr Reddy's Laboratories REDY.NS reported a second-quarter profit that missed analysts' expectations on Tuesday, weighed down by pricing pressure in a competitive North American market,their biggest by revenue.
The company reported a 9.5% fall in its consolidated net profit after tax to 13.42 billion rupees ($159.6 million) for the quarter ended Sept. 30, missing analysts' estimate of 14.01 billion rupees, as per data compiled by LSEG.
The drugmaker's total revenue jumped 16.5% to 80.38 billion rupees, surpassing analysts' estimates of an 11% rise, as its revenue from North America climbed 17%.
DrReddy's largely attributed the sales growth in the region to a rise in volumes but said it was partly offset by price erosion.
Generic drugmakers such as Dr Reddy's, CiplaCIPL.NS and ZydusZYDS.NS havebeen struggling with a slowdown in the United States due to delayed approvals for new generic drug applications andlower pricing amid stiff competition, according to analysts.
Increased inspections of generic drug manufacturing facilities by the Food and Drug Administration has also added to the pressure,analysts said.
However, these drugmakers have been benefitting from strong sales across North America for their generic version of Bristol-Myers Squibb's BMY.N popular cancer treatment drug Revlimid since its launch in 2022.
This, along with other generic drugs used to treat gastrointestinal and cardiovascular issues, boosted sales for Dr Reddy'sin the region.
Revenue from the India business, the company's second-biggest market, climbed 18% to 13.97 billion rupees.
($1 = 84.0710 Indian rupees)
Reporting by Kashish Tandon and Rishika Sadam in Bengaluru; Editing by Savio D'Souza and Janane Venkatraman
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
